Viviscal AminoMar,
does it really help with Increased hair density and growth in women?
research showsPlacebo-controlled trials of the finished Viviscal product reported improvements in target-area hair counts, diameter, or shedding in women. The samples were small, however, ranging from 15 to 96 participants; all identified pivotal trials received Lifes2good support; and the products contained vitamin C, zinc, horsetail, and other ingredients in addition to AminoMar, preventing attribution to AminoMar alone. The outcomes were hair-count and density surrogates rather than durable treatment of a diagnosed alopecia or clinical outcomes, supporting C.
ads claimMarketing may say that AminoMar awakens follicles, creates new hair, or clinically treats hair loss. The evidence actually consists of small trials measuring hair counts, diameter, and shedding after several months with a specific combination product.
Useful facts when choosing a product
- Trials generally used two Viviscal tablets daily for three to six months, with vitamin C, zinc, horsetail, and other ingredients in addition to AminoMar.
- AminoMar content and co-ingredients vary by product, and it is not the same as a biotin 009 or keratin-only product.
- Korean consumers may encounter products through online cross-border purchase or purchasing agents; formal import status, functional-food notification, and Korean labeling should be checked for each listing.
- Because the complex is derived from fish and shellfish, people with seafood allergy should avoid it; pregnancy and lactation safety data are limited. These issues are separate from efficacy.
What the research actually shows
The 2012 Ablon trial randomized 15 women, 10 to active product and 5 to placebo, and reported increased terminal hairs in a 4 cm² target area after six months. A 60-person three-month trial by Ablon and a 40-person six-month trial by Ablon and Dayan also reported improvements in hair count or diameter. The 96-person multisite Rizer trial reported less shedding at three months and greater vellus-like hair diameter at six months, although the between-group shedding difference was no longer significant at six months. These studies tested finished Viviscal products and received full or direct Lifes2good support, so they do not provide independent replication or isolate AminoMar.
Why this is classified as C (49)
Repeated quantitative signals in small placebo-controlled trials rule out D or unknown. Universal manufacturer sponsorship, a proprietary finished combination, surrogate outcomes, and no large independent replication cap the grade at C with 49 points under rules 2-b and 1.
Counterpoint. A possibility of adjunctive improvement in hair measures remains for a specific Viviscal product in women with self-perceived thinning. This does not extend to diagnosed alopecia treatment or an isolated AminoMar effect.
Rejudgment record. New verdict — Small placebo trials are positive, but all are Lifes2good-funded finished-combination studies using hair surrogates without large independent replication, capping the grade at C
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved hair count, density, or diameter in women with self-perceived thinning | C | Small product-funded placebo trials are positive, but evidence is limited to a combination formula and surrogate measures. |
| Clinical treatment of diagnosed female alopecia | ? | Pivotal trials enrolled self-perceived temporary thinning and did not directly establish clinical outcomes for a specific diagnosed alopecia. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Ablon G. 2012 | Randomized double-blind placebo-controlled trial | 5 | Research grant from Lifes2good | Terminal and vellus hair counts in a 4 cm² scalp target and self-assessment | Reported increased terminal hair counts at days 90 and 180, but this was a very small finished-product trial. | Key; concentrated |
| Ablon G. 2015 | Three-month randomized double-blind placebo-controlled trial | 60 | Supported by Lifes2good | Target-area terminal hair counts and shed-hair counts | Reported increased terminal hairs and reduced shedding in the active group. | Key; concentrated |
| Rizer RL et al. 2015 | Multisite randomized double-blind placebo-controlled trial | 96 | Fully funded by Lifes2good; a company employee was a coauthor | Hair shedding and fiber diameter | Reported less shedding at three months and greater vellus-like diameter at six months, but the six-month between-group shedding difference was not significant. | Key; concentrated |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] Viviscal AminoMar x hair density and growth in women — Evidence Grade C·49. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/viviscal-aminomar-womens-hair-density-growth/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.